NCT06753981Recruiting
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
Source: ClinicalTrials.gov · Last updated 31 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 48 (estimated)
- First submitted
- 22 Dec 2024
- Start date
- 10 Dec 2024
- Primary completion date
- 14 Nov 2026
- Lead sponsor
- Qianfoshan Hospital
- NCT number
- NCT06753981
What you commit to
- Study type: Observational
- Planned participants: 48
- From 10 Dec 2024 to the primary completion date, 14 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- PAH patients with concurrent malignant tumors
Other illness
- Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
- Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary
- Suffering from mental illness or cognitive impairment
- Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia
Other
- Pregnant or lactating women
- Currently participating in other interventional clinical studies
- Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.
Who the study is looking for
- Consent and sign the informed consent form
- Non-low-risk PAH treatment-naive patients
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.